Last checked at 
LONDON (Alliance News) - Drugmaker Hikma Pharmaceuticals PLC on Wednesday said it has launched generic Xeloda cancer treatment tablets in the US.
Hikma said the tablets have been launched through its West-Ward Pharmaceuticals Corp affiliate in the US and have been indicated for patients with Dukes' C colon cancer, as a monotherapy for metastatic colorectal cancer and for metastatic breast cancer.
"We are very pleased to have this product approval from the Columbus portfolio. We have an excellent pipeline of differentiated products and proven R&D, supply chain and operational capabilities that we expect will drive accelerated and sustainable future growth," said Hikma Chairman and Chief Executive Said Darawazah.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
